LUCD - NASDAQ
Lucid Diagnostics Inc.
$1.02
+0.49%Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
At a Glance
Live SnapshotLucid Diagnostics Inc. Profit Bridge
Profitability Analysis
Gross Margin
Negative gross margin indicates the company is losing money on each sale—unsustainable long-term.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
Lucid Diagnostics Inc. Income Statement
LUCD • NASDAQ
| Lucid Diagnostics Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||
4.7M | 4.3M | 2.4M | 377K | 500K | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||
(7.5M) | (8.3M) | (8.5M) | (3.6M) | (585K) | (0.0) | (0.0) | (0.0) | |
-2.8M | -3.9M | -6.1M | -3.2M | -85K | 0.0 | 0.0 | 0.0 | |
OPERATING INCOME | ||||||||
(46.8M) | (42.1M) | (42.4M) | (52.9M) | (27.3M) | (8.3M) | (4.4M) | (1.1M) | |
(41.6B) | (36.6B) | (35.7M) | (39.8M) | (18M) | (2.8M) | (958.7K) | (410.3K) | |
(5.7B) | (6M) | (7.3M) | (11.5M) | (9.3M) | (5.4M) | (3.5M) | (715.6K) | |
-49.6M | -46.1M | -48.5M | -56.2M | -27.4M | -8.3M | -4.4M | -1.1M | |
PRE-TAX INCOME | ||||||||
(22K) | (26K) | (416K) | (8K) | (659K) | (0.0) | (0.0) | (0.0) | |
364K | 296K | 8K | 80K | -659K | 0.0 | 0.0 | 0.0 | |
-47.2B | -36.6B | -478K | (1.6M) | (0.0) | (0.0) | (278.0) | (0.0) | |
-8.4M | 523K | -4.2M | 0.0 | -659K | 0.0 | 0.0 | 0.0 | |
-58M | -45.5M | -52.7M | -56.2M | -28.1M | -8.3M | -4.4M | -1.1M | |
NET INCOME | ||||||||
-58M | -45.5M | -52.7M | -56.2M | -28.1M | -8.3M | -4.4M | -1.1M |
SEC Filings
LUCD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 24, 2026 | April 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 23, 2026 | April 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 26, 2026 | March 26, 2026 | 2026 | |
S-3/A S-3/A (Amended) N/A | March 26, 2026 | March 26, 2026 | ||
10-K 10-K 2025 FY FY | March 25, 2026 | December 31, 2025 | 2025 | |
S-3 S-3 N/A | December 05, 2025 | December 05, 2025 | ||
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your LUCD research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.